NEWS
- Pharma & Biotech News #PharmaBuzz
- Weekly News Recap #Phispers
- Recent Product Approvals #GreenLight
- Quality Compliance Alerts #Warning!
- All News #Library
DRUGS & DEVELOPMENTS
MARKET INTEL by PharmaCompass
Create content with us, ask us
By PharmaCompass
2018-09-13
Impressions: 103 Article
In a deal valued up to US$ 735 million, consisting of an upfront payment of US$ 635 million and up to US$ 100 million in cash for potential sales-based milestones, Emergent Biosolutions acquired Adapt Pharma to access its flagship product Narcan (naloxone Hydrochlroride) Nasal Spray — the first and only US Food and Drug Administration (FDA) approved nasal form of naloxone for the emergency treatment of a known or suspected opioid overdose.
The acquisition is designed to help Emergent expand its presence within the public health threats market to respond to the opioid crisis, which has been declared a public health emergency by the US government.
Click here to view the major deals in August 2018 (FREE Excel version available)
Narcan is often carried by police officers and medical teams and was approved in 2015. Earlier this year, the US Surgeon General released a public health advisory urging more Americans to carry naloxone.
The purchase of Adapt Pharma is expected to generate revenues of US$ 200 million to US$ 220 million and to be accretive to adjusted net income and EBITDA in 2019.
Just weeks earlier, Emergent announced an all-cash US$ 270 million acquisition of specialty vaccines company PaxVax. The acquisition will add two revenue-generating FDA-licensed vaccines that protect against cholera and typhoid fever to Emergent’s vaccine portfolio. These vaccines are expected to generate revenues of US$ 70 million to US$ 90 million in 2019.
Click here to view the major deals in August 2018 (FREE Excel version available)
The PharmaCompass Newsletter – Sign Up, Stay Ahead
Feedback, help us to improve. Click here
Image Credit : Top Pharma & Biotech Deals - Aug 2018 by PharmaCompass is licensed under CC BY 2.0
“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”
